Bioscience Research Group Seminar Series

Here are the full details of The University of Hertfordshire's Bioscience Research Group seminars, sponsored by the Biochemical Society.

Our next seminar will take place on 27 October 2021

Macrophage targeted immunotherapy - Clinical development of bexmarilimab

Dr Maija Hollmén (MediCity Research Laboratory, University of Turku, Finland)

Significant discoveries in the field of tumorimmunology have revolutionised cancer treatment in the last few years and are now offering unforeseen prospects of cure for some patients. Despite these advances, the majority (up to 80%) of patients remain refractory to current immune checkpoint inhibitor therapy for mainly unknown reasons. Targeting macrophages to break the immune-tolerance of tumors and help activate host immune defenses is the next cutting edge in cancer immunotherapy. Macrophage-targeted therapies may be used as monotherapy or in combination with a variety of other treatments, and open entirely new therapeutic options for people without a cure. One such target is Clever-1 (also known as Stabilin-1 and FEEL-1), a large glycoprotein receptor that is expressed by immunosuppressive macrophages and monocytes, and which is involved in scavenging, angiogenesis and cell adhesion. Previously, we have found that the growth of multiple solid tumors in mice is significantly impaired when Clever-1 is genetically removed from macrophages. Moreover, immunotherapeutic Clever-1 blockade reactivated the anti-tumor CD8+T-cell response with comparable therapeutic efficacy to PD-1 checkpoint blockade.

Currently, a Clever-1 targeting humanized antibody, bexmarilimab, is in clinical development to evaluate its safety, tolerability and preliminary efficacy in patients with advanced solid tumors (Phase I/II; NCT03733990, MATINS).

Please contact Maria Dimitriadi for further details.